AmirAli Talasaz - Guardant Health President COO, Director
| GH Stock | USD 16.67 0.28 1.71% |
President
Mr. AmirAli Talasaz, Ph.D., is a President, Chief Operating Officer, Director of the Company. AmirAli is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to cofounding Guardant, he was Senior Director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of nextgeneration genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University. since 2017.
| Age | 44 |
| Tenure | 7 years |
| Address | 3100 Hanover Street, Palo Alto, CA, United States, 94304 |
| Phone | 855 698 8887 |
| Web | https://guardanthealth.com |
AmirAli Talasaz Latest Insider Activity
Tracking and analyzing the buying and selling activities of AmirAli Talasaz against Guardant Health stock is an integral part of due diligence when investing in Guardant Health. AmirAli Talasaz insider activity provides valuable insight into whether Guardant Health is net buyers or sellers over its current business cycle. Note, Guardant Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Guardant Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
AmirAli Talasaz over a year ago Purchase by AmirAli Talasaz of 27813 shares of Guardant Health |
Guardant Health Management Efficiency
The company has Return on Asset (ROA) of (0.1764) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1764. This is way below average. Likewise, it shows a return on total equity (ROE) of (4.3813) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.37. As of now, Guardant Health's Debt To Assets are increasing as compared to previous years. The Guardant Health's current Fixed Asset Turnover is estimated to increase to 2.51, while Total Assets are projected to decrease to under 1.4 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Trisha Coady | HealthStream | 48 | |
| Thomas Schultz | HealthStream | 49 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Scott McQuigg | HealthStream | 50 | |
| Jonathan Soldan | HealthEquity | 32 | |
| Jill MS | Simulations Plus | 55 | |
| Lee Neumann | Agiliti | 48 | |
| Robert Creviston | Agiliti | 57 | |
| Nicholas Meeks | Streamline Health Solutions | 32 | |
| Nicholas McGrane | Evolent Health | 49 | |
| Thomas Gibson | Streamline Health Solutions | 60 | |
| Scott Christensen | Agiliti | 59 | |
| Michael Collier | HealthStream | 48 | |
| Angelique Hill | HealthEquity | 55 | |
| John DiBella | Simulations Plus | 35 | |
| Leif Pedersen | Certara | 59 | |
| Steven Jackson | National Research Corp | 42 | |
| Patrick PharmD | Certara | 53 | |
| Jeffery Doster | HealthStream | 51 | |
| Michael Sousa | HealthStream | 55 | |
| Frode Jensen | HealthEquity | 64 | |
Management Performance
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 |
Guardant Health Leadership Team
Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AmirAli Talasaz, President COO, Director | ||
| Richard Lanman, Chief Medical Officer | ||
| Marcel Roche, Vice President - Finance | ||
| Ian Clark, Lead Independent Director | ||
| Leena DasYoung, General Manager,Chief LUNAR Officer | ||
| John Saia, Chief Secretary | ||
| DEREK BERTOCCI, CFO | ||
| Terilyn Monroe, Chief Officer | ||
| Craig MD, Chief Officer | ||
| Andy Ament, VP Operations | ||
| Kumud Kalia, Chief Officer | ||
| Michael Bell, Chief Officer | ||
| Michael Wiley, Chief Legal Officer | ||
| Aaref Hilaly, Independent Director | ||
| Darl Moreland, Senior Quality | ||
| Jennifer Higgins, Vice Affairs | ||
| Dipchand Nishar, Independent Director | ||
| Christopher Freeman, Chief Officer | ||
| Helmy Eltoukhy, CoCEO CoFounder | ||
| Mark Jacobstein, Chief User Engagement Officer | ||
| Bahija Jallal, Director | ||
| Stanley Meresman, Independent Director | ||
| Lynn Lewis, IR Contact Officer | ||
| Darya Chudova, VP Technology | ||
| Samir Kaul, Independent Director |
Guardant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.85) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 2.21 B | ||||
| Shares Outstanding | 121.71 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 93.77 % | ||||
| Number Of Shares Shorted | 7.64 M | ||||
| Price To Earning | (12.01) X |
Guardant Health Investors Sentiment
The influence of Guardant Health's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Guardant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Guardant Health's public news can be used to forecast risks associated with an investment in Guardant. The trend in average sentiment can be used to explain how an investor holding Guardant can time the market purely based on public headlines and social activities around Guardant Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Guardant Health's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Guardant Health's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Guardant Health's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Guardant Health.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Guardant Health in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Guardant Health's short interest history, or implied volatility extrapolated from Guardant Health options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.036 | Quarterly Revenue Growth 0.222 | Return On Assets (0.18) | Return On Equity (4.38) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.